REGN (Regeneron Pharmaceuticals Inc)
Insider Trading Activity
Every open-market purchase and sale reported by REGN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Kathryn Guarini | Director | MIXED | — | — |
| 2026-09-03 | Marion McCourt | EVP Commercial | Sell | — | — |
| 2026-08-21 | JOSEPH J LAROSA | EVP General Counsel and Secret | MIXED | — | — |
| 2026-08-20 | Christopher R. Fenimore | EVP Finance CFO | MIXED | — | — |
| 2026-08-12 | Huda Y Zoghbi | Director | MIXED | — | — |
| 2026-08-12 | Kathryn Guarini | Director | MIXED | — | — |
| 2026-07-07 | ARTHUR F RYAN | Director | Sell | — | — |
| 2026-05-04 | ARTHUR F RYAN | Director | Sell | — | — |
| 2026-04-03 | ARTHUR F RYAN | Director | Sell | — | — |
| 2026-03-03 | ARTHUR F RYAN | Director | Sell | — | — |
| 2026-02-23 | Huda Y Zoghbi | Director | MIXED | — | — |
| 2026-02-11 | ARTHUR F RYAN | Director | Sell | — | — |
| 2026-02-11 | Jason Pitofsky | SVP Controller | MIXED | — | — |
| 2026-01-08 | Bonnie L Bassler | Director | MIXED | — | — |
| 2026-01-06 | CHRISTINE A POON | Director | A | — | — |
| 2026-01-06 | Bonnie L Bassler | Director | A | — | — |
| 2026-01-06 | MICHAEL S BROWN | Director | A | — | — |
| 2026-01-06 | N ANTHONY COLES | Director | A | — | — |
| 2026-01-06 | ARTHUR F RYAN | Director | A | — | — |
| 2026-01-06 | JOSEPH L GOLDSTEIN | Director | A | — | — |
| 2026-01-06 | David P Schenkein | Director | A | — | — |
| 2026-01-06 | Kathryn Guarini | Director | A | — | — |
| 2026-01-06 | GEORGE L SING | Director | A | — | — |
| 2026-01-06 | Craig B. Thompson | Director | A | — | — |
| 2026-01-06 | Huda Y Zoghbi | Director | A | — | — |
| 2026-01-05 | LEONARD S SCHLEIFER | Bd. Co-Chair, President & CEO | MIXED | — | — |
| 2026-01-05 | GEORGE YANCOPOULOS | Bd. Co-Chair, President & CSO | MIXED | — | — |
| 2025-12-31 | GEORGE L SING | Director | MIXED | — | — |
| 2025-12-11 | LEONARD S SCHLEIFER | Bd. Co-Chair, President & CEO | MIXED | — | — |
| 2025-12-11 | GEORGE YANCOPOULOS | Bd. Co-Chair, President & CSO | MIXED | — | — |
| 2025-12-11 | Marion McCourt | EVP Commercial | F | — | — |
| 2025-12-11 | ANDREW J MURPHY | EVP Research | F | — | — |
| 2025-12-11 | Daniel P Van Plew | EVP & General Mgr, Industrial | F | — | — |
| 2025-12-09 | Christopher R. Fenimore | EVP Finance CFO | MIXED | — | — |
| 2025-12-09 | JOSEPH J LAROSA | EVP General Counsel and Secret | MIXED | — | — |
| 2025-12-09 | Marion McCourt | EVP Commercial | MIXED | — | — |
| 2025-12-09 | ANDREW J MURPHY | EVP Research | MIXED | — | — |
| 2025-12-09 | Daniel P Van Plew | EVP & General Mgr, Industrial | MIXED | — | — |
| 2025-12-09 | Jason Pitofsky | VP Controller | MIXED | — | — |
| 2025-11-24 | Bonnie L Bassler | Director | MIXED | — | — |
| 2025-11-24 | JOSEPH J LAROSA | EVP General Counsel and Secret | MIXED | — | — |
| 2025-11-10 | Jason Pitofsky | VP Controller | Sell | — | — |
| 2025-10-31 | ANDREW J MURPHY | EVP Research | MIXED | — | — |
| 2025-10-31 | CHRISTINE A POON | Director | MIXED | — | — |
| 2025-01-06 | Bonnie L Bassler | Director | A | — | — |
| 2025-01-06 | MICHAEL S BROWN | Director | A | — | — |
| 2025-01-06 | JOSEPH L GOLDSTEIN | Director | A | — | — |
| 2025-01-06 | Kathryn Guarini | Director | A | — | — |
| 2025-01-06 | CHRISTINE A POON | Director | MIXED | — | — |
| 2025-01-06 | ARTHUR F RYAN | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 15,816,953 | — |
| — | Bd. Co-Chair, President & CSO | 510,460 | — |
| — | Bd. Co-Chair, President & CEO | 370,577 | — |
| — | Director | 336,039 | — |
| — | 10%+ Owner | 279,766 | — |
| — | SVP Administration & Asst Secr | 70,086 | — |
| — | EVP Research and Development | 53,434 | — |
| — | EVP Research | 52,208 | — |
| — | EVP General Counsel and Secret | 45,805 | — |
| — | EVP & General Mgr, Industrial | 34,049 | — |
| — | Director | 31,407 | — |
| — | SVP Clinical Development & Reg | 27,388 | — |
| — | EVP Commercial | 26,913 | — |
| — | EVP Finance CFO | 24,608 | — |
| — | EVP Finance CFO | 23,963 | — |
| — | VP Reg Dev & Med Safety | 21,844 | — |
| — | SVP General Counsel and Secret | 20,039 | — |
| — | SVP Strategy Investor Relation | 18,767 | — |
| — | Director | 17,303 | — |
| — | EVP Commercial | 12,222 | — |
| — | VP Controller and Asst Treasur | 10,995 | — |
| — | Director | 10,612 | — |
| — | Director | 9,000 | — |
| — | Director | 7,865 | — |
| — | Director | 7,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the REGN quote page; the site-wide leaderboard is on the insider transactions hub.